Pattern Recognition Receptors (PRRs) Expression and Activation in COVID-19 and Long COVID: From SARS-CoV-2 Escape Mechanisms to Emerging PRR-Targeted Immunotherapies
Microorganisms · 17.09.2025 · 13 (9) · 2176
DOI: 10.3390/microorganisms13092176 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 17.09.2025. Verfasst von Luca Maddaloni und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 300 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sapienza University of Rome, University of Rome La Sapienza, EU funding within the Next Generation EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is recognized by pattern recognition receptors (PRRs), which play a vital role in triggering innate immune responses such as the production of type I and III interferons (IFNs). While modest PRR activation helps to defend against SARS-CoV-2, excessive or sustained activation can cause harmful inflammation and contribute to severe Coronavirus Disease 2019 (COVID-19). Altered expression of Toll-like receptors (TLRs), which are among the most important members of the PRR family members, particularly TLRs 2, 3, 4, 7, 8 and 9, has been strongly linked to COVID-19 severity. Furthermore, retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), collectively known as RLRs (RIG-I-like receptors), act as sensors that detect SARS-CoV-2 RNA. The expression of these receptors, as well as that of different DNA sensors, varies in patients infected with SARS-CoV-2. Changes in PRR expression, particularly that of TLRs, cyclic GMP-AMP synthase (cGAS), and the stimulator of interferon genes (STING), have also been shown to play a role in the development and persistence of long COVID (LC). However, SARS-CoV-2 has evolved strategies to evade PRR recognition and subsequent signaling pathway activation, contributing to the IFN response dysregulation observed in SARS-CoV-2-infected patients. Nevertheless, PRR agonists and antagonists remain promising therapeutic targets for SARS-CoV-2 infection. This review aims to describe the PRRs involved in recognizing SARS-CoV-2, explore their expression during SARS-CoV-2 infection, and examine their role in determining the severity of both COVID-19 and long-term manifestations of the disease. It also describes the strategies developed by SARS-CoV-2 to evade PRR recognition and activation. Moreover, given the considerable interest in modulating PRR activity as a novel immunotherapy approach, this review will provide a description of PRR agonists and antagonists that have been investigated as antiviral strategies against SARS-CoV-2. This review aims to explore the complex interplay between PRRs and SARS-CoV-2 in depth, considering its implications for prognostic biomarkers, targeted therapeutic strategies and the mechanistic understanding of long LC. Additionally, it outlines future perspectives that could help to address knowledge gaps in PRR-mediated responses during SARS-CoV-2 infection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.
- Laboratory of Virology, Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
- USCR-SAG Unit, Higher Institute of Biotechnology, University of Monastir, Monastir 5000, Tunisia.
- Department of Biological Sciences, College of Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
- Istituto Pasteur Italia-Fondazione Cenci Bolognetti, 00161 Rome, Italy.
ORCID-Profile: Luca Maddaloni, Ginevra Bugani, Matteo Fracella, Alessandra D'Auria, Letizia Santinelli, Manel Ben M'Hadheb, Alessandra Pierangeli, Carolina Scagnolari
Förderung
- Sapienza University of Rome
- University of Rome La Sapienza
- EU funding within the Next Generation EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
Zitieren
APA
Maddaloni, L., Bugani, G., Fracella, M., Bitossi, C., D'Auria, A., Aloisi, F., Azri, A., Santinelli, L., Ben M'Hadheb, M., Pierangeli, A., Frasca, F., & Scagnolari, C. (2025). Pattern Recognition Receptors (PRRs) Expression and Activation in COVID-19 and Long COVID: From SARS-CoV-2 Escape Mechanisms to Emerging PRR-Targeted Immunotherapies. Microorganisms, 13(9), 2176. https://doi.org/10.3390/microorganisms13092176
Vancouver
Maddaloni L, Bugani G, Fracella M, Bitossi C, D'Auria A, Aloisi F, et al. Pattern Recognition Receptors (PRRs) Expression and Activation in COVID-19 and Long COVID: From SARS-CoV-2 Escape Mechanisms to Emerging PRR-Targeted Immunotherapies. Microorganisms. 2025;13(9):2176. doi:10.3390/microorganisms13092176
BibTeX
@article{Maddaloni2025,
author = {Maddaloni, Luca and Bugani, Ginevra and Fracella, Matteo and Bitossi, Camilla and D'Auria, Alessandra and Aloisi, Francesca and Azri, Abir and Santinelli, Letizia and Ben M'Hadheb, Manel and Pierangeli, Alessandra and Frasca, Federica and Scagnolari, Carolina},
title = {Pattern Recognition Receptors (PRRs) Expression and Activation in COVID-19 and Long COVID: From SARS-CoV-2 Escape Mechanisms to Emerging PRR-Targeted Immunotherapies},
journal = {Microorganisms},
year = {2025},
volume = {13},
number = {9},
pages = {2176},
doi = {10.3390/microorganisms13092176}
}
EUVIMED